Di Lorenzo Rosaria, Amoretti Alessandra, Forghieri Matilde, Fiorini Fiorenza, Genedani Susanna, Rigatelli Marco
Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, Policl via del Pozzo 71, 141100, Modena, Italy.
Exp Clin Psychopharmacol. 2007 Dec;15(6):569-75. doi: 10.1037/1064-1297.15.6.569.
A retrospective study was conducted to examine aripiprazole's effectiveness and safety in a naturalistic treatment setting in both inpatients and outpatients affected by schizophrenia and other psychotic disorders. All patients with schizophrenia, schizoaffective and delusional disorders, and schizoid and schizotypal personality disorders treated with aripiprazole from March 1, 2005, to March 1, 2006, in the authors' community mental health service were divided into outpatient (n=26) and inpatient (n=17) groups; the average treatment periods were 204 days and 25 days, respectively. Effectiveness was evaluated by improvement of symptoms (a 25% reduction of Brief Psychiatric Rating Scale [BPRS] score from baseline) and functioning level (a 50% increase of Global Assessment of Functioning [GAF] scale score from baseline), as well as dropout rate. Adverse effects and their impact on treatment course were also evaluated. The final scores of the 2 scales showed a statistically significant difference from baseline (BPRS: p<.001 in the 2 groups; GAF: p<.005 in inpatients, p<.001 in outpatients). The average improvements in BPRS and GAF were 54% and 35%, respectively, in outpatients and 71% and 71% in inpatients. Side effects included anxiety, psychomotor agitation, insomnia, and psychotic symptom worsening. The dropout rate was 24% in inpatients and 23% in outpatients, largely because of the aforementioned side effects. The data, though limited by the small sample and naturalistic methodology, suggest that aripiprazole may be effective for both long- and short-term treatment, with a greater improvement among inpatients and a similar dropout rate between groups.
开展了一项回顾性研究，以检验阿立哌唑在精神分裂症及其他精神障碍的住院患者和门诊患者的自然治疗环境中的有效性和安全性。2005年3月1日至2006年3月1日期间，在作者所在社区精神卫生服务机构接受阿立哌唑治疗的所有精神分裂症、分裂情感性障碍和妄想性障碍以及分裂样和分裂型人格障碍患者被分为门诊组（n = 26）和住院组（n = 17）；平均治疗期分别为204天和25天。通过症状改善（简明精神病评定量表[BPRS]评分较基线降低25%）、功能水平改善（总体功能评定量表[GAF]评分较基线增加50%）以及脱落率来评估有效性。还评估了不良反应及其对治疗过程的影响。两个量表的最终评分与基线相比有统计学显著差异（BPRS：两组均p <.001；GAF：住院患者p <.005，门诊患者p <.001）。门诊患者BPRS和GAF的平均改善率分别为54%和35%，住院患者分别为71%和71%。副作用包括焦虑、精神运动性激越、失眠和精神病性症状恶化。住院患者的脱落率为24%，门诊患者为23%，主要是由于上述副作用。尽管数据受小样本和自然主义方法的限制，但表明阿立哌唑可能对长期和短期治疗均有效，住院患者改善更大，两组间脱落率相似。
